[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"periodontitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:periodontitis":26},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,148,0,25,[9,41,68,105,137,158,187,211,244,270,290,317,352,383,412,434,459,485,505,526,547,571,594,613,631],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100644263","evaluation-of-masticatory-performance-in-patients-with-periodontitis-100644263",false,"NCT07665489","Evaluation of Masticatory Performance in Patients With Periodontitis","PAROCHEW","Inclusion Criteria:\n\n* Patients followed at the university hospital (CHU) with a diagnosis of periodontitis.\n* No objection from the patient to participate in the study.\n* Patients able to speak and understand French.\n\nExclusion Criteria:\n\n* Minors.\n* Patients under legal protection (guardianship, trusteeship, or judicial protection measures).\n* Pregnant or breastfeeding women.\n* Patients who refuse to participate in the study.","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","The objective of this observational study is to assess the correlation between the severity of periodontal involvement and masticatory performance in patients with periodontitis.\n\nThe secondary objectives are to identify periodontal parameters that may be associated with a reduction in masticatory performance.\n\nThis study includes a single group.\n\nParticipants will be asked to perform a masticatory performance test consisting of chewing a piece of gum for 20 cycles.",[25,26,27],"Periodontitis, Adult","Periodontitis","Oral Disease","NOT_YET_RECRUITING","2026-06-30",{"date":31,"type":32},"2026-07-01","ACTUAL",{"date":34,"type":21},"2026-06-01",{"date":36,"type":21},"2027-06-01",{"name":38,"class":39},"University Hospital, Clermont-Ferrand","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":40},"100593995","prf-as-adjunct-to-subgingival-instrumentation-in-step-2-periodontal-therapy-100593995","NCT07013682","PRF as Adjunct to Subgingival Instrumentation in Step 2 Periodontal Therapy","Platelet Rich Fibrin Adjunctive to Non-surgical Periodontal Therapy: a 6-month Split-mouth Randomized Controlled Clinical Trial","PRFSTEP2","Inclusion Criteria:\n\n* Men and women aged ≥ 18 years\n* Periodontitis stage II-IV, grade A\u002FB\u002FC, generalized\n* Presence of at least 20 teeth (excluding wisdom teeth)\n* Absence of removable dentures\n* Patients willing to provide written informed consent and to complete the 6- month study follow-up\n\nExclusion Criteria:\n\n* Patients already participating in other clinical trials\n* Periodontal treatment in the previous 12 months\n* Antibiotic treatment 3 months prior to study entry\n* Antibiotic prophylaxis required for dental treatment\n* Current use of any medication that may affect the clinical features of periodontitis\n* Pregnant\u002Flactating\n* Any condition that prevents venipuncture\n* Not willing to venous puncture\n* Current cancer treatment\n* History of radiation in the head-neck area",true,{"count":51,"type":21},20,"INTERVENTIONAL",[54],"NA","Periodontitis is characterized by a chronic, multifactorial inflammatory process driven by dysbiotic plaque biofilms. It is recognized as the most common chronic inflammatory non-communicable disease in humans. The advanced and severe forms of periodontitis have an estimated prevalence of 7.4%, while milder forms can affect up to 50% of the population.\n\nIf left untreated, periodontitis can lead to tooth loss. However, it is largely preventable and treatable with mechanical non-surgical periodontal therapy. To improve periodontal healing and thus clinical attachment gain after non-surgical therapy, adjunctive bioactive formulations such as enamel matrix derivatives, sodium hypochlorite, locally delivered antimicrobials, or hyaluronic acid have recently been proposed. However, these agents are non-autologous formulations and expensive.\n\nPlatelet-rich fibrin (PRF) acts as a scaffold that inhibits the early migration of epithelial cells into the periodontal tissues. Its regenerative properties are primarily due to its ability to promote angiogenesis. This ability is attributed to the 3D fibrin matrix, which can simultaneously transport several cytokines and growth factors. These include vascular endothelial growth factor (VEGF), insulin growth factor (IGF), transforming growth factor β1 (TGF-β1) and platelet-derived growth factor (PDGF). PRF further shows antibacterial properties and accelerates soft tissue healing. So far PRF is not routinely used in periodontal non-surgical therapy.\n\nThe aim of this 6-month, split-mouth randomized clinical trial including 20 patients is to test whether PRF can improve the results after non-surgical therapy.",[26,57,58],"Periodontal Inflammation","Periodontal Attachment Loss","RECRUITING",{"date":61,"type":32},"2026-07-02",{"date":63,"type":32},"2025-05-01",{"date":65,"type":21},"2027-12-24",{"name":67,"class":39},"University of Bern",{"id":69,"slug":70,"hasResults":12,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":49,"sex":17,"minAge":74,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":52,"phases":77,"briefSummary":78,"conditions":79,"keywords":83,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":40},"100644993","breaking-the-cycle-real-time-family-oral-microbial-transmission-patterns-as-intervention-targets-100644993","NCT07674888","Breaking the Cycle: Real-Time Family Oral Microbial Transmission Patterns as Intervention Targets","Inclusion Criteria:\n\n* Families with at least two children aged 5-12 years living in the same household.\n* least one parent or guardian diagnosed with Stage II or III periodontitis requiring non-surgical periodontal therapy.\n* At least one child who has undergone caries treatment and is considered at high risk for disease recurrence.\n* Willingness of all participating household members to provide oral samples and participate in study procedures.\n* Ability of participants or their legal guardians to provide informed consent, and assent from children where applicable.\n\nExclusion Criteria:\n\n* Children living in multiple households or shared-custody arrangements during the study period.\n* Households unable to complete study visits or follow-up procedures.\n* Individuals unwilling or unable to comply with study procedures.\n* Individuals who do not provide informed consent or assent, where applicable.\n* Medical or behavioral conditions that, in the opinion of the investigators, would preclude safe participation in the study.","5 Years",{"count":76,"type":21},225,[54],"This study aims to understand how oral bacteria that cause tooth decay and gum disease spread among family members and whether treating multiple family members can reduce the return of these bacteria after dental treatment.\n\nFamilies with children aged 5-12 years will be recruited from university dental clinics. Participants will be assigned to one of three treatment groups: treatment for the child only, treatment for the child and parents, or treatment for all family members. Researchers will collect oral bacterial samples from family members before and after treatment and will monitor close-contact interactions within the household using wearable proximity-tracking devices.\n\nThe study will also collect information about oral health habits, family interactions, and environmental factors that may influence bacterial transmission. By combining bacterial DNA analysis with information about family contact patterns, researchers hope to better understand how oral bacteria are shared within households and whether family-based treatment approaches can reduce bacterial recolonization after dental therapy.\n\nThe results of this study may help improve strategies for preventing childhood tooth decay and gum disease by addressing family-level sources of bacterial transmission.",[80,26,81,82],"Dental Caries","Oral Microbiome","Bacterial Transmission",[84,85,86,87,88,89,90,91,92,93,94,95,96],"family microbial transmission","Oral microbiome","Plaque recolonization","Pediatric oral health","Real-time proximity tracking","Ultrawide Band (UWB)","Oral bacterial transmission","Intergenerational pathogen transfer","Biofilm disruption","Periodontal disease","Family-based intervention","Microbial source tracking","Oral Health","2026-06-25",{"date":29,"type":32},{"date":100,"type":21},"2026-09-30",{"date":102,"type":21},"2028-06-30",{"name":104,"class":39},"University of Alberta",{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":114,"conditions":115,"keywords":124,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":40},"100638972","periodontal-disease-in-rare-renal-disorders-perio-ra-re-100638972","NCT07575347","Periodontal Disease in Rare Renal Disorders (PERIO-RA-RE)","Periodontal Inflammation in Rare Renal Disorders - A Cross-Sectional Controlled Observational Study Assessing the Burden and Phenotypes of Periodontal Disease","PERIO-RA-RE","Inclusion Criteria:\n\n* Age ≥18 years\n* Ability to provide written informed consent\n* At least 10 natural teeth present\n* Belonging to one of the predefined study groups:\n\n  1. Alport syndrome (genetically or clinically confirmed)\n  2. Fabry disease (enzymatically or genetically confirmed)\n  3. Tuberous sclerosis complex (according to established clinical or genetic criteria)\n  4. Systemic lupus erythematosus defined according to the 2019 EULAR\u002FACR or SLICC 2012 classification criteria, with renal involvement defined by at least one of the following: \\[1\\] Biopsy-proven lupus nephritis, \\[2\\] Persistent proteinuria (\\>0.5 g\u002Fday or equivalent), \\[3\\] Active urinary sediment (hematuria and\u002For cellular casts) consistent with lupus nephritis\n  5. Chronic kidney disease (CKD) of non-rare etiology: defined according to KDIGO criteria (eGFR \\\u003C60 ml\u002Fmin\u002F1.73 m² and\u002For markers of kidney damage)\n  6. Individuals without CKD, recruited from clinical or dental care settings as non-CKD controls\n\nExclusion Criteria:\n\n* Periodontal treatment within the last 6 months\n* Antibiotic therapy within the last 4 weeks\n* Pregnancy\n* Conditions precluding periodontal examination\n* Inability to comply with study procedures",{"count":20,"type":21},"This study aims to evaluate the burden and phenotypic spectrum of periodontal disease in patients with rare kidney disorders (such as Alport syndrome, Fabry disease, and tuberous sclerosis complex) and systemic lupus erythematosus (SLE), compared with chronic kidney disease (CKD) controls and population controls.\n\nThis is a cross-sectional, case-control observational study. Participants will undergo a single structured evaluation including a full-mouth periodontal examination, a clinical questionnaire, and collection of relevant clinical and nephrological data.\n\nThe primary objective is to compare the prevalence of periodontitis across study groups. Secondary objectives include characterization of periodontal disease severity, prevalence of gingivitis and xerostomia, and identification of disease-specific oral phenotypes.\n\nExploratory analyses will assess associations between periodontal disease and clinical variables such as kidney function, proteinuria, and immunosuppressive exposure.",[116,26,117,118,119,120,121,122,123],"Periodontal Disease","CKD","Chronic Kidney Disease","Alport Syndrome","Fabry Disease","Lupus or SLE","Tuberous Sclerosis Complex (TSC)","Systemic Lupus Erythematosus (SLE)",[116,26,117,125,126,127,122,118],"Rare Kidney Diseases","Alport syndrome","Systemic Lupus Erythematosus","2026-06-24",{"date":130,"type":32},"2026-06-26",{"date":132,"type":32},"2026-05-04",{"date":134,"type":21},"2027-12-31",{"name":136,"class":39},"Stefan Lujinschi",{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":4},"100644776","sterify-gel-as-an-adjunct-to-non-surgical-periodontal-therapy-in-periodontitis-100644776","NCT07672665","Sterify Gel as an Adjunct to Non-Surgical Periodontal Therapy in Periodontitis","The Adjunctive Effect of a Mucoadhesive Polymeric Hydrogel to Non-surgical Periodontal Therapy: a Retrospective Analysis","Sterify","Inclusion Criteria:\n\n* Adult patients aged \\>18 years\n* Diagnosis of stage II, III, or IV periodontitis\n* Non-smokers\n* Negative medical history\n* Patients treated with scaling and root planing\u002Fminimally invasive non-surgical periodontal therapy plus mucoadhesive polymeric hydrogel\n* Patients enrolled in supportive periodontal care\n\nExclusion Criteria:\n\n* Smokers\n* Pregnancy\n* Surgical re-treatment during the maintenance period","100 Years",{"count":51,"type":21},"This retrospective observational study will evaluate the clinical response to Sterify Gel, a sterile mucoadhesive polymeric hydrogel, when used as an adjunct to non-surgical periodontal therapy in adult patients with stage II, III, or IV periodontitis.\n\nThe study will analyze already existing anonymized clinical records from patients treated at the Periodontal Unit of IRCCS Ospedale San Raffaele in Milan, Italy. Patients included in the analysis received scaling and root planing\u002Fminimally invasive non-surgical periodontal therapy, followed by local application of Sterify Gel into periodontal pockets with probing depth greater than 4 mm.\n\nThe main objective is to assess reduction in periodontal pocket depth from baseline to 6, 12, and 24 weeks. Other periodontal clinical parameters, including clinical attachment level, gingival recession, bleeding, plaque score, tooth mobility, and furcation involvement, will also be evaluated.",[26],"2026-06-22",{"date":151,"type":32},"2026-06-29",{"date":153,"type":21},"2026-06",{"date":155,"type":21},"2026-12",{"name":157,"class":39},"IRCCS San Raffaele",{"id":159,"slug":160,"hasResults":12,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":52,"phases":167,"briefSummary":168,"conditions":169,"keywords":172,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":185,"locationsCount":40},"100590437","comparative-effects-of-two-oral-antiseptics-used-as-an-adjuvant-in-the-treatment-of-periodontitis-100590437","NCT06967402","Comparative Effects of Two Oral Antiseptics Used as an Adjuvant in the Treatment of Periodontitis","Comparative Clinical Efficacy and Microbiological Effects of Two Oral Antiseptics Used as an Adjuvant in the Treatment of Severe Periodontitis","Inclusion Criteria:\n\n* Consenting patients with at least 6 evaluable teeth in each quadrant, including minimum 1 molar and 1 premolar.\n* Generalized stage II-III periodontitis patients.\n* Baseline BOP \\> 25%.\n* No known allergy or adverse effects to CHX or CPC\n* Non-smokers, non-orthodontic patients, no concurrent or past antibiotics\u002Fmedication known to affect periodontal status (i.e. calcium antagonists, phenytoin)\u002Fanti-inflammatory therapy (i.e. NASIDs) in the last 3 months, pregnant\u002Fbreastfeeding, compliance to study procedures.\n* ASA class I-II patients.\n* Either non-diabetic or with controlled diabetes (HbA1C\\\u003C7).\n* Normal\u002FElevated blood pressure (AHA - Systolic \\\u003C130mmHg; Diastolic \\\u003C80mmHg).\n* No radiation\u002Fchemotherapy in the past 5 years\n* No immunosuppression including drug induced immunosuppression.\n* No participation in other clinical studies in the last 4 weeks.\n* No administration of CHX or CPC in the last 3 months\n* No periodontal treatment in the last 3 months.\n\nExclusion Criteria:\n\n* Unable to provide written consent.\n* Non-compliant study procedures.\n* Patients with medical (including psychiatric) and pharmacotherapeutic histories that, in the investigator's opinion, may compromise the protocol.\n* Patients requiring antibiotics prophylaxis for dental procedures.\n* Patients with self-reported pregnancy or patients who are breastfeeding.\n* Patients with history of use of systemic antibiotics, in combination with any form of periodontal treatment, within the past 3 months.\n* Patients with uncontrolled endocrine disease.\n* Patients who are not compliant with the review protocol, leading to deviation of more than 1 week.\n* Patients requiring the admission of systemic antibiotics, in combination with any form of dental treatment, during the study period.",{"count":166,"type":21},60,[54],"The focus of this study is on two types of mouthwashes - one containing a chlorhexidine (CHX) at 0.2% (CHX), and the other one containing CHX at a lower concentration of 0.12% with cetylpyridinium chloride (CPC). Both mouthwashes are used to help in the treatment of gum disease. CHX has been known for a long time for its effectiveness against plaque and mouth inflammation. It could inhibit and even kill them. However higher concentrations of CHX comes with unwanted side effect including altered taste, teeth staining and irritation in the mouth. Interestingly, these side effects seem to occur less frequently when a lower concentration CHX solution is used. CPC also combats bacteria by adhering quickly to the surfaces inside your mouth, although it has less substantivity than CHX, it has been shown to reduce plaque and gum inflammation effectively, and it typically causes fewer side effects than CHX. We hypothesize that this new formulation of CHX 0.12%+CPC mouthwash is non-inferior to CHX 0.2% in terms of its anti-plaque and anti-inflammatory properties while presenting with less side effects after 21 days of use. Microbiological samples and fluids from periodontal pockets will be collected before and after treatment for analysis of microbiological effects.",[26,170,171],"Periodontitis Stage II","Periodontitis Stage III",[173,174,175,26,176,177,178],"Mouthwash","Chlorhexidine","CPC","Mouthrinse","cetylpyridinium chloride","Oral antiseptic","2026-06-21",{"date":181,"type":32},"2026-06-23",{"date":183,"type":32},"2025-11-20",{"date":134,"type":21},{"name":186,"class":39},"The University of Hong Kong",{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":12,"sex":17,"minAge":194,"maxAge":195,"enrollmentInfo":196,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":197,"conditions":198,"keywords":199,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":40},"100615049","anti-inflammatory-nutrition-on-the-outcomes-of-non-surgical-periodontal-therapy-100615049","NCT07287540","Anti-inflammatory Nutrition on the Outcomes of Non-surgical Periodontal Therapy","Evaluation of the Effects of Anti-inflammatory Nutrition on the Outcomes of Non-surgical Periodontal Therapy in Individuals With Periodontitis","Inclusion Criteria:\n\n* Being systemically healthy\n* Not smoking\n* Not using anti-inflammatory drugs in the last 3 months, antibiotics, or systemic corticosteroids in the last 6 months\n* Not being pregnant or lactating\n* Not having received periodontal treatment in the last 6 months\n* Having at least 20 teeth in the mouth\n* Being diagnosed with periodontitis by the investigator\n* Having a dietary inflammatory index \\>0\n\nExclusion Criteria:\n\n* Having a systemic disease\n* Smoking\n* Using anti-inflammatory drugs within the last 3 months, antibiotics within the last 6 months, or systemic corticosteroids\n* Being pregnant or lactating\n* Having received periodontal treatment within the last 6 months\n* Having fewer than 20 teeth in the mouth\n* No periodontitis","20 Years","65 Years",{"count":20,"type":21},"This study aimed to determine the effect of anti-inflammatory nutrition on non-surgical periodontal treatment in individuals with periodontitis by evaluating gingival crevicular fluid (GCF) and serum biomarkers and clinical periodontal parameters.\n\nA total of 100 volunteers identified as having a pro-inflammatory diet (Q3 and Q4) will be included in the study. Individuals will be assigned to two groups. These groups will then be further divided into two groups based on whether or not they will receive anti-inflammatory nutrition education. Group Q3-1 (n=25) will receive non-surgical periodontal treatment and anti-inflammatory nutrition education. Group Q3-2 (n=25) will receive only non-surgical periodontal treatment. Group Q4-1 (n=25) will receive non-surgical periodontal treatment and anti-inflammatory nutrition education. Group Q4-2 (n=25) will receive only non-surgical periodontal treatment. After the periodontal index measurements are completed, the patients will receive non-surgical periodontal treatment. GCF and serum samples, periodontal clinical parameters and Dietary Inflammatory Index will be collected 3 times: at baseline, 1.5 and 3 months after non-surgical periodontal treatment. Levels of interleukin (IL)-1β, IL-10, tumor necrosis factor (TNF)-α, total oxidant status (TOS), total antioxidant status (TAS), and C-reactive protein (CRP) will be assessed from these samples. This will investigate the role of anti-inflammatory nutrition in reducing periodontal inflammation and increasing treatment success.",[26],[200,201,202],"periodontitis","diet inflammatory index","anti-inflammatory nutrition","2026-06-18",{"date":181,"type":32},{"date":206,"type":32},"2025-11-22",{"date":208,"type":21},"2026-07-04",{"name":210,"class":39},"Recep Tayyip Erdogan University Training and Research Hospital",{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":49,"sex":17,"minAge":18,"maxAge":195,"enrollmentInfo":219,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":221,"conditions":222,"keywords":224,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":40},"100641785","salivary-biomarkers-in-periodontal-disease-progression-100641785","NCT07661784","Salivary Biomarkers in Periodontal Disease Progression","Evaluation of Salivary Biomarkers Associated With Bone Remodeling in the Transition From Periodontal Health to Disease","PERIO-BIO","Inclusion Criteria:\n\nAdults aged 18-65 years Systemically healthy individuals Individuals classified as periodontally healthy, gingivitis, or periodontitis according to clinical periodontal examination Ability and willingness to provide informed consent\n\nExclusion Criteria:\n\nPresence of systemic diseases affecting periodontal status (e.g., diabetes mellitus, immunological disorders) Use of antibiotics or anti-inflammatory drugs within the last 3 months History of periodontal treatment within the last 6 months Pregnancy or lactation Smoking (optional ) Any condition that may affect salivary biomarker levels",{"count":220,"type":21},240,"This study aims to evaluate salivary biomarkers associated with bone remodeling during the transition from periodontal health to disease. Periodontal diseases are characterized by chronic inflammation that can lead to connective tissue destruction and alveolar bone loss. Although diagnosis is primarily based on clinical and radiographic findings, these methods may not fully reflect disease activity or progression.\n\nIn this observational study, individuals with periodontal health, gingivitis, and periodontitis will be included. Salivary levels of IL-17, IL-23, IL-6, TGF-β, RANKL, and OPG will be measured using ELISA. The relationship between these biomarkers and periodontal disease stage and grade will be analyzed.\n\nThe results are expected to improve understanding of the biological mechanisms underlying periodontal disease progression and to assess the potential role of salivary biomarkers in early diagnosis and personalized treatment approaches.",[116,223,26],"Gingivitis and Periodontal Diseases",[116,225,26,226,227,228,229,230,231,232,233,234,235],"Gingivitis","Salivary Biomarkers","Bone Remodeling","Interleukin-17 (IL-17)","Interleukin-23 (IL-23)","Interleukin-6 (IL-6)","Transforming Growth Factor Beta (TGF-β)","RANKL","Osteoprotegerin (OPG)","ELISA","Non-invasive Diagnosis","2026-06-16",{"date":149,"type":32},{"date":239,"type":32},"2025-07-10",{"date":241,"type":21},"2026-08-30",{"name":243,"class":39},"Suleyman Demirel University",{"id":245,"slug":246,"hasResults":12,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":12,"sex":17,"minAge":251,"maxAge":252,"enrollmentInfo":253,"targetDuration":4,"studyType":52,"phases":255,"briefSummary":256,"conditions":257,"keywords":259,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":263,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":40},"100641352","effectiveness-of-subgingival-instrumentation-on-delaying-end-stage-renal-disease-among-chronic-kidney-disease-patients-100641352","NCT07635797","Effectiveness of Subgingival Instrumentation on Delaying End-stage Renal Disease Among Chronic Kidney Disease Patients","Effectiveness of Subgingival Instrumentation on Delaying End-stage Renal Disease Among Chronic Kidney Disease Patients: A Non-Randomized Clinical Study","Inclusion Criteria:\n\n* Patients aged 40-70 years.\n* Type 2 diabetes mellitus with chronic kidney disease and currently on oral hypoglycaemic agents.\n* Diagnosed with Stage IV or V (eGFR between 15-20 mL\u002Fmin\u002F1.73m²).\n* Not undergoing dialysis.\n* Presence of ≥20 natural teeth.\n* Diagnosed with moderate (Stage II) (as per 2017 World Workshop classification) (Interdental CAL at site of greatest loss \\>2mm but \\\u003C5 mm in ≥ 2 non-adjacent teeth).\n* Willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Patients already undergoing haemodialysis or renal transplantation.\n* Patients on insulin therapy or taking SGLT2 inhibitors and GLP-1 receptor agonists.\n* HbA1c level \\>8 %.\n* Any Periodontal therapy within past 6 months.\n* Immunocompromised patients.\n* Any history of tobacco use.\n* Pregnant or lactating women.","40 Years","70 Years",{"count":254,"type":21},40,[54],"Chronic kidney disease (CKD) and periodontitis share a bidirectional inflammatory relationship, with cytokines such as IL-6, TNF-α, and hsCRP driving progression in both conditions. Non-surgical periodontal therapy (NSPT) has shown reductions in systemic inflammatory markers with emerging evidence of improved renal function, yet robust randomized controlled trials targeting pre-dialysis stage IV-V diabetic CKD patients remain lacking. In the Indian context, where diabetes-related CKD is rapidly rising and access to dialysis is limited, there is a clear lacuna in literature regarding the effectiveness of NSPT in delaying progression to end-stage renal disease. Hence, the present non-randomized clinical study is undertaken to address this gap.",[118,26,258],"End Stage Renal Disease (ESRD)",[118,260,26,261,262],"Subgingival Instrumentation","End Stage Renal Disease","Dialysis",{"date":203,"type":32},{"date":265,"type":21},"2026-07",{"date":267,"type":21},"2027-12",{"name":269,"class":39},"Postgraduate Institute of Dental Sciences Rohtak",{"id":271,"slug":272,"hasResults":12,"nctId":273,"briefTitle":274,"officialTitle":274,"acronym":275,"eligibilityCriteria":276,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":277,"targetDuration":4,"studyType":52,"phases":279,"briefSummary":280,"conditions":281,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":286,"completionDateStruct":287,"leadSponsor":289,"locationsCount":40},"100642636","evaluation-of-the-impact-of-periodontitis-and-its-treatment-on-swallowing-functions-and-oral-quality-of-life-100642636","NCT07651579","Evaluation of the Impact of Periodontitis and Its Treatment on Swallowing Functions and Oral Quality of Life","FI-PAROCROC","Inclusion Criteria:\n\n* Patients treated at the university hospital and diagnosed with periodontitis\n* Adult patients who have provided informed consent\n* Patients enrolled in a social security system\n* Patients who speak and understand French.\n\nExclusion Criteria:\n\n* Minors\n* Pregnant or breastfeeding patients\n* Patients under legal protection or conservatorship\n* Patients who refuse to participate in the study",{"count":278,"type":21},44,[54],"The objective of this single-center prospective study is to evaluate the impact of periodontal treatment on masticatory performance in patients with periodontitis.\n\nParticipants will be asked to complete several questionnaires related to their oral health and quality of life. Functional masticatory tests and salivary flow measurements will also be performed.",[26,282,283],"Periodontal Diseases","Quality of Life","2026-06-11",{"date":236,"type":32},{"date":34,"type":21},{"date":288,"type":21},"2028-06-01",{"name":38,"class":39},{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":49,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":298,"targetDuration":4,"studyType":52,"phases":300,"briefSummary":301,"conditions":302,"keywords":304,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":40},"100516585","intraoral-scanners-as-periodontal-and-dental-pathologies-diagnosis-tools-100516585","NCT06006429","Intraoral Scanners as Periodontal and Dental Pathologies Diagnosis Tools","Digital Extraction and Scientific Visualization of Clinical Characteristics From 3D Data From Intraoral Scanners for Dental and Periodontal Pathologies Research : Computer Formalization and Feasibility Study","Odonto3D","Inclusion Criteria:\n\n* adultes\n* consulting the Dental Care Service of the university hospital of Reims\n* presenting at least one gingival recession\n* presenting at least 10 pairs of opposing teeth\n* speaking French\n* who signed the informed consent form\n* affiliated to the French Social Security system\n\nExclusion Criteria:\n\nPatients presenting :\n\n* pregnancy or breastfeeding\n* orthodontic treatments\n* patients under legal protection, trusteeship or guardianship\n* unable to understand auto-questionnary",{"count":299,"type":21},30,[54],"Periodontal diseases and dental pathologies are highly prevalent oral diseases. Thirty-three to fifty percent of adult population presented at least one untreated caries and more than 50% of French population are affected by severe periodontitis. These diseases affect dental organ or periodontal attached system but could have negative impact on general health, quality of life, word and individual well-being. Association between chronic diseases as diabetes, rheumatoid arthritis, cardiovascular diseases, and oral health have been well investigated. Dental and periodontal diagnosis is dependent of various clinical parameters time consuming and dependent operator. It represents a public health challenge. Informatic analysis detecting diseases could be a time gain and a more precise diagnosis tool. Today, any software or algorithm allow automatized detection, clinical qualitative or quantitative indices recording while these informations are present in numeric models",[26,225,80,303],"Diagnosis",[305,306,307,308],"Periodontal diseases","Dental caries","intra-oral camera","diagnosis",{"date":310,"type":32},"2026-06-12",{"date":312,"type":32},"2022-05-11",{"date":314,"type":21},"2027-12-11",{"name":316,"class":39},"CHU de Reims",{"id":318,"slug":319,"hasResults":12,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":323,"eligibilityCriteria":324,"healthyVolunteers":12,"sex":325,"minAge":4,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":52,"phases":328,"briefSummary":331,"conditions":332,"keywords":336,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":40},"100625608","phase-2-xylitol-and-the-prevention-of-periodontal-disease-and-preterm-birth-trial-100625608","NCT07424846","Xylitol and the Prevention of Periodontal Disease and Preterm Birth Trial","Xylitol and the Prevention of Periodontal Disease and Preterm Birth (XaPPP) Trial","XaPPP","Inclusion Criteria:\n\n* Able to provide informed consent. For those under 18 years of age, an approval will additionally be sought from the parent or guardian\n* Less than 20 weeks' gestation (by best obstetric estimate)\n* At least 20 natural teeth\n* Planning to deliver at one of the health facilities within the XaPPP trial\n* Receiving antenatal obstetric care at one of the 8 health districts\n* Willing to chew two pieces of gum thrice daily for 5 minutes after the morning, day and evening meals throughout pregnancy\n* Willing to attend all study visits\n* Willing to provide biospecimens (oral, vaginal, placental, breast milk)\n* Willing to undergo at least two dental exams including oral microbiota sampling at study enrolment \\\u003C20 weeks of pregnancy, 28-30 weeks of pregnancy, and 6-8 weeks after giving birth\n* Willing to have their child undergo follow up through at least 12 months after birth including neurodevelopmental examination(s)\n* Speaks Chichewa or English\n\nAll patients who meet inclusion criteria will be approached without regard to sex, race, ethnicity, parents' country of origin, or religious preferences.\n\nExclusion Criteria:\n\n* Those who upon screening and enrolment but dislike the taste of the gum and state they will not chew the gum throughout pregnancy\n* Gravidae with known or suspected non-viable pregnancy (including life threatening congenital anomalies such as cardiac, neurological or others)\n* Pregnant individual has a life-threatening diagnosis such as cancer requiring treatment during pregnancy\n* Pregnant women with a known or suspected morbidly adherent placenta (such as placenta accrete, increta and percreta)\n* Known allergy to xylitol","FEMALE",{"count":327,"type":21},6000,[329,330],"PHASE2","PHASE3","The ground-breaking Prevention of Prematurity and Xylitol (PPaX) cluster randomized controlled clinical trial was conducted in Lilongwe, Malawi and enrolled approximately 10,069 pregnant individuals seeking to evaluate the impact of xylitol-containing chewing gum compared to no chewing gum on reducing the occurrence of maternal periodontal disease, preterm birth, and low birthweight offspring. The premise of this study centers upon the numerous publications supporting a strong association between maternal periodontal disease and preterm birth. Given that xylitol-containing chewing gum is considered a prebiotic and known to reduce cariogenic and periodontopathic bacteria, the study evaluated and discovered a statistically significant reduction in maternal periodontal disease, preterm birth, and low birthweight offspring among pregnant individuals who chewed xylitol-containing chewing gum.\n\nWhile PPaX demonstrated the efficacy of xylitol to reduce preterm birth (PTB), the study had important limitations: (a) PPaX was an unblinded cluster-randomized study with only 8 clusters, 4 with xylitol-containing chewing gum and 4 without any gum (not placebo-controlled); (b) PPaX used a suboptimal dose of 2 grams of xylitol daily which may have reduced the effectiveness of the intervention given that recent literature suggests 5-10 grams\u002Fday more effectively improve oral health; and (c) PPaX did not evaluate infant mortality nor early neurodevelopmental outcomes. Notably, reducing fetal exposure to periodontal disease (PD) as well as PTB may improve neurodevelopmental outcomes for offspring as both prematurity and fetal exposure to inflammation are well-documented risk factors for neurodevelopmental delay (NDD) and infant mortality.\n\nThe investigators will conduct a double-blind, placebo-controlled, individually randomized clinical trial with 3 arms among Malawian pregnant individuals (n=6000) at \\\u003C20 weeks of pregnancy with the co-primary outcomes being the incidence of PTB and low birthweight offspring. The 3 study arms (n=2000 each) will be (a) an optimized dose of xylitol-containing chewing gum (6.4 grams\u002Fday), (b) the PPaX trial xylitol dose (2.1 grams\u002Fday), or (c) flavored sorbitol gum base (placebo control). This trial overcomes the PPaX trial's limitations and will definitively answer whether xylitol prevents PTB in Malawi. The investigators will additionally collect biospecimens from a random sampling of the participants for biobanking for later analysis of inflammatory and microbiome alterations that may occur with xylitol exposure compared with placebo. The investigators hypothesize that pregnant individuals who chew xylitol-containing chewing gum will have a significant reduction in periodontal disease metrics at 28-30 weeks' gestation (e.g. bleeding on probing) as well as offspring with improved neurodevelopmental outcomes as assessed by the Bayley Scales of Infant and Toddler Development 4th edition and reduced risk of adverse pregnancy outcomes including preterm birth.",[333,334,26,225,335],"Preterm Birth","Low Birthweight Neonate","Developmental Delay",[337,338,339,340,200,341,342],"xylitol","preterm birth","prematurity","pregnancy","periodontal disease","chewing gum","2026-06-05",{"date":345,"type":32},"2026-06-09",{"date":347,"type":32},"2026-03-26",{"date":349,"type":21},"2030-09-30",{"name":351,"class":39},"University of Washington",{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":4,"eligibilityCriteria":358,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":195,"enrollmentInfo":359,"targetDuration":4,"studyType":52,"phases":361,"briefSummary":362,"conditions":363,"keywords":370,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":378,"completionDateStruct":379,"leadSponsor":381,"locationsCount":40},"100637561","hyaluronic-acid-as-an-adjunct-to-non-surgical-periodontal-therapy-in-smokers-100637561","NCT07597213","Hyaluronic Acid as an Adjunct to Non-Surgical Periodontal Therapy in Smokers","The Effect of Adjunctive Use of Hyaluronic Acid in Non-Surgical Periodontal Treatment in Smoking Patients","Inclusion Criteria:\n\n1. Individuals who sign the informed consent form\n2. Participants who are systemically healthy\n3. Participants who smoke (for \\>5 years and ≥10 cigarettes per day)\n4. Participants diagnosed with Stage III or Stage IV periodontitis\n5. Participants with at least 20 natural teeth present in the mouth (excluding third molars)\n6. Participants with two non-adjacent interproximal sites in each quadrant of either jaw, presenting probing depth (PD) and clinical attachment level (CAL) ≥6 mm, and with no caries, restorations, or furcation involvement\n\nExclusion Criteria:\n\n1. Individuals who do not sign the informed consent form\n2. Individuals having any systemic disease\n3. Participants who have used antibiotics within the last 3 months\n4. Participants who have received any periodontal treatment within 6 months prior to the study\n5. Participants who are pregnant or lactating",{"count":360,"type":21},23,[54],"The goal of this clinical trial is to evaluate whether hyaluronic acid (HA) improves periodontal healing in people with periodontal disease who smoke. Moreover, the effects of HA on biomolecules and bacteria levels will be assessed during the follow up period.\n\nThe main questions it will answer are:\n\nWill periodontal sites treated with HA gel after non-surgical periodontal treatment (NSPT) lead to better outcomes in clinical parameters compared to the sites treated with NSPT only in smokers?\n\nWill adjunctive use of HA gel reduce oxidative stress markers and bacteria levels during follow-up?\n\nResearchers will compare periodontal sites receiving NSPT with adjunctive HA gel application to sites receiving NSPT alone to determine whether HA provides additional clinical, biochemical and microbiological benefits.\n\nParticipants will:\n\n* first receive full-mouth NSPT then, randomization will be performed in selected jaw to determine the test sites. These two interproximal test sites will additionally receive HA gel application.\n* attend follow-up visits at 1, 3 and 6 months for clinical periodontal measurements and to provide gingival crevicular fluid samples (GCF) and subgingival samples.\n\nThe GCF samples will be evaluated for Metallothionein (MT) and 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels and subgingival samples for periodontal pathogens.",[364,365,366,367,368,369,26],"Hyaluronic Acid","Periodontal Therapy","Oral Microbiota","Oxidative Stress","Metallothionein","8-OHdG",[371,200,372,373,369,374,375],"hyaluronic acid","periodontal pathogens","metallothionein","Non-surgical periodontal treatment","split-mouth study","2026-06-03",{"date":343,"type":32},{"date":153,"type":21},{"date":380,"type":21},"2028-07",{"name":382,"class":39},"Marmara University",{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":195,"enrollmentInfo":391,"targetDuration":4,"studyType":52,"phases":392,"briefSummary":393,"conditions":394,"keywords":395,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":40},"100643347","photodynamic-therapy-as-an-adjunct-in-periodontal-treatment-100643347","NCT07633405","Photodynamic Therapy as an Adjunct in Periodontal Treatment","Clinical Evaluation of Photodynamic Therapy as an Adjunct to Scaling and Root Planing in the Treatment of Periodontal Disease: A Split-Mouth Randomized Controlled Clinical Trial","PDT-PERIO","Inclusion Criteria:\n\n* Adults aged 18 to 65 years.\n* Diagnosis of Stage I, II, III, or IV periodontitis according to the 2018 World Workshop Classification.\n* Presence of at least two hemiarches with periodontal pockets ≥5 mm suitable for a split-mouth design.\n* Systemically healthy individuals.\n* No periodontal treatment received within the previous 6 months.\n* No use of antibiotics, anti-inflammatory drugs, or antiseptic mouth rinses within the previous 3 months.\n* Ability and willingness to provide written informed consent and attend follow-up visits.\n\nExclusion Criteria:\n\n* Uncontrolled systemic diseases that may affect healing or immune response.\n* Use of antibiotics, corticosteroids, or immunosuppressive medications within the previous 3 months.\n* Active smokers consuming more than 10 cigarettes per day.\n* Pregnant or breastfeeding women.\n* Presence of dental implants, defective restorations, or teeth with Grade III mobility in the selected study sites.\n* Known allergy to toluidine blue O or any component of the photosensitizer.\n* Individuals unable or unwilling to attend the 30-day follow-up visit.",{"count":299,"type":21},[54],"This study aims to evaluate the clinical effectiveness of antimicrobial photodynamic therapy (aPDT) as an adjunct to scaling and root planing (SRP) in the treatment of periodontitis. A split-mouth design will be used, in which one hemiarch receives conventional SRP and the contralateral hemiarch receives SRP combined with aPDT. Clinical periodontal parameters, including probing pocket depth (PPD), clinical attachment level (CAL), bleeding on probing (BOP), plaque index (PI), and gingival index (GI), will be assessed at baseline and 30 days after treatment. The study seeks to determine whether adjunctive aPDT improves periodontal outcomes compared with conventional non-surgical periodontal therapy alone.",[26,116],[26,116,396,397,398,399,400,401,402],"Antimicrobial Photodynamic Therapy","Photodynamic Therapy","aPDT","SRP","Clinical attachment level","Low level Laser therapy","Gingival Index","2026-06-02",{"date":405,"type":32},"2026-06-08",{"date":407,"type":21},"2026-07-28",{"date":409,"type":21},"2026-09-27",{"name":411,"class":39},"Universidad Catolica Santiago de Guayaquil",{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":4,"eligibilityCriteria":418,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":195,"enrollmentInfo":419,"targetDuration":4,"studyType":52,"phases":420,"briefSummary":421,"conditions":422,"keywords":426,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":430,"startDateStruct":431,"completionDateStruct":432,"leadSponsor":433,"locationsCount":40},"100643782","adjunctive-hyaluronic-acid-gel-in-non-surgical-periodontal-treatment-of-patients-with-diabetes-mellitus-100643782","NCT07631273","Adjunctive Hyaluronic Acid Gel in Non-Surgical Periodontal Treatment of Patients With Diabetes Mellitus","The Effect of Hyaluronic Acid on Non-Surgical Periodontal Treatment in Patients With Diabetes Mellitus","Inclusion Criteria:\n\n* Individuals who sign the informed consent form\n* Participants diagnosed with diabetes mellitus (HbA1c %7-7.9)\n* Participants without any systemic disease other than DM\n* Participants diagnosed with Stage III or Stage IV periodontitis\n* Nonsmokers\n* Participants with at least 15 natural teeth present in the mouth (excluding third molars)\n* Participants in either of the jaws, in both quadrants, having two non-adjacent interproximal sites with probing depth and clinical attachment level ≥6 mm with no caries, restorations or furcation involvement\n\nExclusion Criteria:\n\n* Individuals who do not sign the informed consent form\n* Ongoing drug therapy that might have an impact on the clinical signs and symptoms of periodontitis\n* Participants have received any periodontal treatment within 6 months prior to the study\n* Participants who have used antibiotics within the last 3 months\n* Smokers\n* Participants who are pregnant or lactating",{"count":360,"type":21},[54],"The goal of this clinical trial is to evaluate whether the adjunctive use of hyaluronic acid (HA) improves periodontal healing in people with diabetes mellitus and periodontitis. The effects of HA on biomolecules and bacteria levels will be assessed during the follow-up period.\n\nThe main questions the study will answer are:\n\n* Will periodontal sites treated with non-surgical periodontal treatment (NSPT) plus HA gel show better clinical periodontal parameters than sites treated with only NSPT in patients with diabetes and periodontitis?\n* will HA gel have additional effect on reducing inflammation or collagen markers, and bacteria levels during follow-up?\n\nResearchers will compare periodontal sites receiving NSPT with adjunctive HA gel application to sites receiving NSPT alone to determine whether HA provides additional clinical, biochemical and microbiological benefits.\n\nParticipants will:\n\n* provide recent HbA1c test results.\n* then, the participants will receive full-mouth NSPT then, randomization will be performed for the selected jaw for test sites. These two interproximal test sites will additionally receive HA application.\n* attend follow-up visits at 1, 3 and 6 months for clinical periodontal measurements and to provide gingival crevicular fluid samples (GCF) and subgingival samples.\n\nThe GCF samples will be evaluated for interleukin-34 (IL-34) and beta C-terminal telopeptide (β-CTX) levels and subgingival samples for periodontal pathogens.",[26,423,364,366,424,425],"Diabetes Mellitus","IL-34","β-CTX",[26,427,428,364,429,424,425,372],"diabetes mellitus","Non-surgical Periodontal Treatment","Split-mouth Study",{"date":405,"type":32},{"date":153,"type":21},{"date":380,"type":21},{"name":382,"class":39},{"id":435,"slug":436,"hasResults":12,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":12,"sex":17,"minAge":441,"maxAge":442,"enrollmentInfo":443,"targetDuration":4,"studyType":52,"phases":445,"briefSummary":446,"conditions":447,"keywords":450,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":454,"startDateStruct":455,"completionDateStruct":456,"leadSponsor":458,"locationsCount":40},"100638375","motivational-interviewing-and-subgingival-instrumentation-outcomes-in-periodontitis-100638375","NCT07618533","Motivational Interviewing and Subgingival Instrumentation Outcomes in Periodontitis","Effect of Motivational Interviewing on the Outcomes of Subgingival Instrumentation in Patients With Periodontitis","Inclusion Criteria:\n\n• Systemically healthy Patients with age group 30-50 years diagnosed with (Stage I-III) periodontitis.\n\nExclusion Criteria:\n\n* Systemic diseases that may affect periodontal disease progression or outcome of treatment\n* Patients on long term antibiotics\n* Pregnant and lactating women\n* Female patients with history of menopause\n* Current orthodontic treatment or planning to undergo orthodontic treatment during study","30 Years","50 Years",{"count":444,"type":21},66,[54],"Motivational Interviewing (MI) represents a patient centered counselling approach designed to facilitate behaviour change by guiding patients through the exploration and resolution of ambivalence toward positive health actions. Adapting OARS microskills (open ended questions fostering dialogue, affirmations building self-efficacy, reflective listening mirroring emotions, summarization making commitments) intertwined with the RULE framework (resisting the righting reflex, understanding personal motivations, empathic listening, empowering autonomy) helps cultivate patient's intrinsic motivation for sustained oral hygiene adherence. It effectively resolves ambivalence toward plaque control behaviours essential for periodontitis management. Grounded in MI's core spirit of equal partnership, evocation of inner values, acceptance and compassionate support, this approach fosters long term adherence to treatment. This is in contrast to oral hygiene instructions that typically employ a directive advice giving method, where clinicians provide patients with prescriptive guidance on maintaining optimal oral hygiene practices. Periodontitis staging, as defined by the 2017 World Workshop classification, delineates disease severity (Stages I-III), complexity of management, and extent of involvement, while grading (A-C) offers a prognostic indicator of the risk for future progression based on factors such as rate of advancement and responsiveness to therapy. Integrating motivational interviewing (MI) with periodontitis staging and grading creates a structured framework from diagnosis to patient centered action, enhancing adherence to stage specific treatment plans. This study seeks to investigate the influence of MI on Clinical outcomes, Patient motivation, Patient related outcomes and Patient's Self-efficacy in oral hygiene following subgingival instrumentation among patients stratified by periodontitis stage. By doing so, it aims to explore the potential of behavior change interventions to yield not only clinical improvements but also broader health benefits in the management of periodontitis.",[448,26,449],"Motivational Interviewing","Oral Hygiene",[451,452,453],"Motivational interviewing","Periodontitis staging and grading","Treatment adherence",{"date":376,"type":32},{"date":130,"type":21},{"date":457,"type":21},"2027-12-27",{"name":269,"class":39},{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":4,"eligibilityCriteria":465,"healthyVolunteers":12,"sex":17,"minAge":441,"maxAge":466,"enrollmentInfo":467,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":469,"conditions":470,"keywords":475,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":481,"startDateStruct":482,"completionDateStruct":483,"leadSponsor":484,"locationsCount":4},"100639187","impact-of-distress-level-sleep-quality-and-occlusal-trauma-on-periodontal-status-among-bruxers-100639187","NCT07615153","Impact of Distress Level, Sleep Quality and Occlusal Trauma on Periodontal Status Among Bruxers","Impact of Distress Level, Sleep Quality and Occlusal Trauma on Periodontal Status Among Bruxers - a Cross Sectional Study","Inclusion Criteria:\n\nTest Group:\n\n* Adults aged 30-45 years\n* Patients diagnosed with periodontitis according to the 2017 World Workshop classification of periodontal and peri-implant diseases and conditions.\n* Patients who are probable bruxers according to BRUXSCREEN-Q\n* Minimum of 20 natural teeth\n\nControl Group:\n\n* Adults aged 30-45 years\n* Patients diagnosed with periodontitis according to the 2017 World Workshop classification of periodontal and peri-implant diseases and conditions.\n* Patients who are not probable bruxers according to BRUXSCREEN-Q\n* Minimum of 20 natural teeth\n\nExclusion Criteria:\n\n* Systemic conditions affecting periodontium (e.g., diabetes, auto immune disorders)\n* History of drugs having the potential impact on periodontal status like phenytoin, cyclosporin, calcium-channel blockers or antidepressant drugs\n* Patients with pulpal pathology\n* Pregnant or lactating females","45 Years",{"count":468,"type":21},128,"Increased distress levels and impaired sleep quality are known to exacerbate bruxism by enhancing masticatory muscle activity, leading to excessive and prolonged occlusal forces. These abnormal forces may result in occlusal trauma, which can compromise the adaptive capacity of the periodontal tissues by increasing tooth mobility, widening the periodontal ligament space, and accelerating alveolar bone loss, particularly in the presence of existing periodontal inflammation. Although occlusal trauma alone may not initiate periodontal disease, it can act as an important modifying factor in disease progression. Despite the recognized individual associations of distress, sleep quality, bruxism, and periodontal health, limited evidence exists regarding their combined impact on periodontal status among bruxers. Therefore, evaluating the influence of distress level, sleep quality, and occlusal trauma on periodontal status is essential to better understand disease progression and to facilitate comprehensive, multidisciplinary management strategies for individuals with bruxism.",[26,471,472,473,474],"Bruxism","Sleep Quality","Distress Level","Occlusal Trauma",[476,477,478,479,480],"periodontits","bruxism","sleep quality","distress level","occlusal trauma",{"date":376,"type":32},{"date":149,"type":21},{"date":457,"type":21},{"name":269,"class":39},{"id":486,"slug":487,"hasResults":12,"nctId":488,"briefTitle":489,"officialTitle":490,"acronym":4,"eligibilityCriteria":491,"healthyVolunteers":12,"sex":17,"minAge":441,"maxAge":442,"enrollmentInfo":492,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":494,"conditions":495,"keywords":497,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":502,"completionDateStruct":503,"leadSponsor":504,"locationsCount":40},"100638717","psychological-resilience-perceived-stress-and-periodontal-status-among-bruxers-100638717","NCT07615140","Psychological Resilience, Perceived Stress and Periodontal Status Among Bruxers","Psychological Resilience as a Modifier of the Relationship Between Perceived Stress and Periodontal Status Among Bruxers: a Cross-sectional Study","Inclusion Criteria:\n\n* Patients with age group 30-50 years diagnosed with generalized periodontitis.\n* Probable bruxers (as per BruxScreen questionnaire)\n* Presence of minimum 20 teeth excluding third molars\n* Able to read\u002Funderstand Hindi or English (for questionnaires)\n\nExclusion Criteria:\n\n* Systemic diseases that may affect periodontal disease progression or outcome of treatment (diabetes, autoimmune diseases)\n* History of Periodontal treatment within last 6 months\n* History of Antibiotic use within the previous 3 months\n* History of Steroid, immunosuppressive and psychiatric drug use\n* Pregnant and lactating women\n* Smoking or substance abuse",{"count":493,"type":21},75,"The present study aims to evaluate psychological resilience as a modifier of the relationship between perceived stress and periodontal status among bruxers. Given that both stress and inflammation share common neuroendocrine and immunological pathways, resilience may play a crucial role in buffering stress-induced periodontal breakdown. Understanding this relationship could shift periodontal management toward a biopsychosocial model, integrating psychological assessment and resilience enhancement with conventional non-surgical therapy. Such insights could help design personalized periodontal care strategies addressing both biological and psychological determinants of disease progression.",[26,471,496],"Perceived Stress",[200,477,498,499],"stress","resilience","2026-05-30",{"date":403,"type":32},{"date":179,"type":21},{"date":155,"type":21},{"name":269,"class":39},{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":4,"eligibilityCriteria":511,"healthyVolunteers":12,"sex":17,"minAge":441,"maxAge":442,"enrollmentInfo":512,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":514,"conditions":515,"keywords":518,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":522,"startDateStruct":523,"completionDateStruct":524,"leadSponsor":525,"locationsCount":40},"100638180","dental-health-state-utilities-and-oral-health-beliefs-in-periodontitis-100638180","NCT07615127","Dental Health State Utilities and Oral Health Beliefs in Periodontitis","Association of Dental Health State Utility Values and Oral Health Beliefs With Staging and Grading of Periodontitis: A Cross-sectional Evaluation","Inclusion Criteria:\n\n* Adult patients with age group 30-50 years diagnosed with generalized periodontitis.\n* Presence of minimum 20 teeth excluding third molars\n* Able to read\u002Funderstand Hindi or English (for questionnaires)\n\nExclusion Criteria:\n\n* Systemic diseases that may affect periodontal disease progression or outcome of treatment (diabetes, autoimmune diseases)\n* History of Periodontal treatment within last 6 months\n* History of Antibiotic use within the previous 3 months\n* History of Steroid, immunosuppressive and psychiatric drug use\n* Pregnant and lactating women\n* History of Smoking or substance abuse",{"count":513,"type":21},112,"This observational, cross-sectional study addresses gaps in periodontal health economics by measuring dental health state utility values (HSUVs) for periodontitis treatment. While Oral Health Related Quality of Life outcomes dominate current research, Health State Utility values are rarely measured and seldom applied . The few existing utility studies are methodologically limited. The primary aim is to measure Health state utility values for periodontal health states using direct elicitation methods ( Standard Gamble) in patients with clinically diagnosed periodontitis. The secondary aim is to examine associations between patient-elicited utility values, clinical periodontal status (CAL, PD, BoP), and psychosocial beliefs from the Health Belief Model including perceived susceptibility, severity, benefits, and barriers. Participants will complete utility tasks and Health belief model questionnaires in a single visit. By integrating preference-based utility measurement with clinical and psychosocial constructs, this study will provide essential data for cost-utility modelling of periodontal interventions and support patient-centered care.",[26,516,517],"Dental Health Utility Value","Health Belief Model",[26,519,520,521],"Denatl health state utility value","oral health beliefs","health beliefs model",{"date":403,"type":32},{"date":179,"type":21},{"date":155,"type":21},{"name":269,"class":39},{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":4,"eligibilityCriteria":532,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":533,"targetDuration":4,"studyType":52,"phases":535,"briefSummary":536,"conditions":537,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":40},"100616360","responsiveness-of-hindi-version-of-oral-health-impact-profile-for-periodontitis-ohip-p-hin-100616360","NCT07304596","Responsiveness of Hindi Version of Oral Health Impact Profile for Periodontitis (OHIP-P-HIN)","Evaluation of Responsiveness of Hindi Version of Oral Health Impact Profile for Periodontitis (OHIP-P-HIN)","Inclusion Criteria:\n\n* ≥18 years of age\n* patients able to understand and complete questionnaires independently\n* confirmed diagnosis of periodontitis\n\nExclusion Criteria:\n\n* Patients with systemic diseases such as acquired immunodeficiency syndrome or diabetes mellitus\n* pregnancy\n* required prophylactic antibiotic coverage prior to dental treatment,\n* patients with bleeding disorders\n* patients who had received non-surgical periodontal therapy within the preceding eight weeks.",{"count":534,"type":21},106,[54],"The distribution- and anchor-based methods will be used to estimate the Minimal Important Difference (MID) of the OHIP-P-HIN. Two established distribution-based approaches, the standardized effect size (ES) and standardized response mean (SRM) will be calculated. The ES is calculated by dividing the mean change scores in the OHIP-P-HIN from baseline by the standard deviation of the baseline scores. And the SRM are computed as ratios of the mean change score divided by its standard deviation. The anchor-based approach will be applied by using the global transition scale as the anchor.",[26,538],"Oral Health Quality of Life (OHQoL) Was Assessed","2026-05-22",{"date":541,"type":32},"2026-05-26",{"date":543,"type":32},"2025-11-12",{"date":545,"type":21},"2026-09",{"name":269,"class":39},{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":252,"enrollmentInfo":554,"targetDuration":4,"studyType":52,"phases":556,"briefSummary":557,"conditions":558,"keywords":559,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":4},"100638262","clinical-study-of-minocycline-hydrochloride-injectable-hydrogel-for-the-treatment-of-periodontitis-100638262","NCT07611630","Clinical Study of Minocycline Hydrochloride Injectable Hydrogel for the Treatment of Periodontitis","Construction of a Long-Acting Sustained-Release Minocycline Hydrochloride Delivery System Based on Hyaluronic Acid-Nanoclay Composite Hydrogel and Its Application in the Treatment of Periodontitis","Inclusion Criteria:\n\n* Clinical Diagnosis: Meets the 2018 International Classification of Periodontal Diseases, diagnosed with Stage III or IV periodontitis.\n* Bone Defect Characteristics: At least one affected tooth presents with a deep periodontal pocket (PPD ≥5 mm), and CBCT imaging confirms the presence of significant vertical bone resorption or angular bone defects (these defect types are most suitable for in-situ hydrogel filling and guided regeneration).\n* Age and General Condition: Aged between 18 and 70 years, any gender, generally in good systemic health.\n\nExclusion Criteria:\n\n* Systemic Interference with Bone Metabolism: Presence of poorly controlled diabetes (HbA1c \\> 7%), osteoporosis, or long-term use of medications affecting bone metabolism such as bisphosphonates or glucocorticoids within the past six months.\n* Local Anatomical Limitations: The affected tooth has a vertical root fracture, severe periapical pathology, or a residual root that is deemed non-restorable and without preservation value.\n* Factors Interfering with Healing: Heavy smokers (average \\> 10 cigarettes per day), as impaired microcirculation can significantly compromise the biological effects of the hydrogel.\n* Special Physiological Periods: Pregnant or breastfeeding women.\n* Drug Allergy: Known allergy to minocycline (MH), hyaluronic acid (HA), or similar chemical components.",{"count":555,"type":21},80,[54],"This study aims to construct and systematically evaluate a multifunctional synergistic drug delivery system based on a hyaluronic acid-nanoclay composite hydrogel to achieve integrated treatment of periodontitis encompassing \"infection control, inflammation regulation, and bone regeneration promotion.\" Through material design, in vitro functional validation, and in vivo efficacy evaluation, the study will elucidate the intrinsic relationships and synergistic mechanisms among \"material structure, controlled drug release, and biological effects\" within this system, thereby providing a theoretical basis and experimental foundation for the development of smart periodontal regenerative materials with clinical translational potential.",[26],[26,560,561],"Hydrogel","Minocycline Hydrochloride","2026-05-20",{"date":564,"type":32},"2026-05-28",{"date":566,"type":21},"2026-05-01",{"date":568,"type":21},"2028-12-31",{"name":570,"class":39},"The First Affiliated Hospital of Xinxiang Medical College",{"id":572,"slug":573,"hasResults":12,"nctId":574,"briefTitle":575,"officialTitle":576,"acronym":4,"eligibilityCriteria":577,"healthyVolunteers":49,"sex":17,"minAge":18,"maxAge":578,"enrollmentInfo":579,"targetDuration":4,"studyType":52,"phases":580,"briefSummary":581,"conditions":582,"keywords":584,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":587,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":40},"100637148","periodontal-inflammation-and-epigenetics-in-obese-individuals-100637148","NCT07610902","Periodontal Inflammation and Epigenetics in Obese Individuals","Association Between Epigenetic Changes, Periodontal Microbiota, And Periodontal Inflammation in Obese Individuals","Inclusion Criteria:\n\n* Adults aged ≥18 years,\n* No history of periodontal therapy in the last 6 months,\n* No use of tobacco,\n* No history of pregnancy lactation or contraceptive medication.\n* Need to have a minimum of 20 teeth.\n\nExclusion Criteria:\n\n* Had antimicrobial\u002Fantiviral therapy in the previous 3 months,\n* History of uncontrolled diabetes,\n* History of rheumatoid arthritis,\n* History of osteoporosis,\n* History of oral cancer,\n* Currently taking hormonal contraception,\n* If pregnant or lactating currently or prior 6 months,\n* Subjects on current weight loss drugs\n* If planning weight reduction surgery during the time of the study\n* Any other condition, disease or therapy with documented influence on oral inflammation and\u002For oral microbial environment.","75 Years",{"count":254,"type":21},[54],"The goal of this study is to investigate the long-term changes in host epigenetic modifications in obese individuals with periodontitis. The aims of the study are:\n\n• To monitor longitudinal changes in host epigenetic modifiers following non-surgical periodontal therapy in periodontitis patients Study subjects would be categorized into two groups, non-obese with periodontitis, and obese with periodontitis. The study will primarily evaluate changes among these groups cross-sectionally, then longitudinally following non-surgical periodontal therapy (deep cleaning) to determine if any changes occur with treatment.",[583,26],"Obesity",[583,26,585,586],"Epigenitics","Periodontal inflammation",{"date":564,"type":32},{"date":589,"type":21},"2026-05-25",{"date":591,"type":21},"2026-12-30",{"name":593,"class":39},"Louisiana State University Health Sciences Center in New Orleans",{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":599,"acronym":4,"eligibilityCriteria":600,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":252,"enrollmentInfo":601,"targetDuration":4,"studyType":52,"phases":602,"briefSummary":603,"conditions":604,"keywords":606,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":609,"startDateStruct":610,"completionDateStruct":611,"leadSponsor":612,"locationsCount":4},"100637686","clinical-study-of-bmp-2-injectable-hydrogel-for-promoting-alveolar-bone-regeneration-100637686","NCT07611617","Clinical Study of BMP-2 Injectable Hydrogel for Promoting Alveolar Bone Regeneration","Study on Injectable Hydrogel Loaded With BMP-2 for Promoting Alveolar Bone Regeneration Induced by Periodontitis","Inclusion Criteria:\n\n* Clinical Diagnosis: Meets the 2018 International Classification of Periodontal Diseases, diagnosed with Stage III or IV periodontitis.\n* Bone Defect Characteristics: At least one affected tooth presents with a deep periodontal pocket (PPD ≥5 mm), and CBCT imaging confirms the presence of significant vertical bone resorption or angular bone defects (these defect types are most suitable for in-situ hydrogel filling and guided regeneration).\n* Age and General Condition: Aged between 18 and 70 years, any gender, generally in good systemic health.\n* Compliance and Consent: The subject is able to understand the study procedures, voluntarily sign the informed consent form, and commit to returning for follow-up visits as required (1, 3, 6, 12 months).\n\nExclusion Criteria:\n\n* Systemic Interference with Bone Metabolism: Presence of poorly controlled diabetes (HbA1c \\> 7%), osteoporosis, or long-term use of medications affecting bone metabolism such as bisphosphonates or glucocorticoids within the past six months.\n* Local Anatomical Limitations: The affected tooth has a vertical root fracture, severe periapical pathology, or a residual root that is deemed non-restorable and without preservation value.\n* Factors Interfering with Healing: Heavy smokers (average \\> 10 cigarettes per day), as impaired microcirculation can significantly compromise the biological effects of the hydrogel.\n* Special Physiological Periods: Pregnant or breastfeeding women.",{"count":555,"type":21},[54],"This project aims to construct an injectable self-healing hydrogel loaded with BMP-2, with optimized gelation time and mechanical strength to meet the requirements for periodontal pocket filling, for the treatment of periodontitis and acceleration of tissue repair, achieving a \"bactericidal-anti-inflammatory-regenerative\" trinity function. This project will provide a novel intelligent material for promoting alveolar bone regeneration in periodontitis and establish a theoretical paradigm for the precise intervention of oral infectious diseases.",[26,605],"Alveolar Bone Loss* \u002F Therapy",[26,607,608,560],"Alveolar Bone Loss* \u002F therapy","BMP-2",{"date":564,"type":32},{"date":566,"type":21},{"date":568,"type":21},{"name":570,"class":39},{"id":614,"slug":615,"hasResults":12,"nctId":616,"briefTitle":617,"officialTitle":618,"acronym":4,"eligibilityCriteria":619,"healthyVolunteers":49,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":620,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":622,"conditions":623,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":625,"lastUpdatePostDateStruct":626,"startDateStruct":627,"completionDateStruct":628,"leadSponsor":629,"locationsCount":4},"100637635","periodontal-status-in-patients-with-oral-lichen-planus-100637635","NCT07597616","Periodontal Status in Patients With Oral Lichen Planus","Studio Retrospettivo Monocentrico di Una Coorte di Pazienti Affetti da Lichen Planus Orale: Caratteristiche, comorbilità e Fattori di Rischio Per la Trasformazione Maligna","Inclusion Criteria:\n\n* OLP group (case)\n\nAge ≥ 18 years Clinical and histopathological diagnosis of OLP according to WHO criteria (2021)\n\nControl group\n\nAge ≥ 18 years Absence of clinical signs of OLP\n\nExclusion Criteria:\n\n* Both groups\n\nOral lichenoid lesions (OLL): oral lichenoid contact reactions (OLCR), lichenoid drug reactions (LDR), lesions associated with food\u002Fsubstances (e.g. cinnamon) Oral lesions associated with graft-versus-host disease (GVHD) History of haematopoietic stem cell transplantation (HSCT) Pregnancy Oncologic patients (including oral cancers) Smokers Diabetes mellitus Obesity Metabolic syndrome Immunosuppressive therapy Medications causing gingival hyperplasia\n\nControl group only\n\nImmune-mediated inflammatory diseases with oral involvement (e.g. psoriasis, systemic or discoid lupus erythematosus) Autoimmune oral diseases other than OLP\n\nOLP group only\n\nImmunosuppressive therapy for conditions other than OLP Autoimmune oral diseases other than OLP",{"count":621,"type":21},176,"This case-control study will enroll 176 patients age- and sex- matched at the Oral Medicine Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome. There will be two groups: The control group will consist of 88 healthy patients enrolled among those routinely attending the dental outpatient clinic. An additional 88 patients diagnosed with OLP will form the case group. Both groups will undergo standard dental examinations, including periodontal probing. The primary objective is to evaluate whether patients with OLP present a higher prevalence and severity of periodontitis compared to healthy subjects. Secondary objectives include the assessment of gingivitis prevalence and RT1 gingival recessions in OLP patients compared with controls. Periodontal status will be assessed using major clinical indices and classified according to the 2017 AAP\u002FEFP case definition. The study aims to contribute evidence on the shared immune-inflammatory mechanisms underlying both conditions, with potential clinical implications for the integrated periodontal management of OLP patients.",[624,26],"Oral Lichen Planus","2026-05-19",{"date":539,"type":32},{"date":562,"type":21},{"date":29,"type":21},{"name":630,"class":39},"Catholic University of the Sacred Heart",{"id":632,"slug":633,"hasResults":12,"nctId":634,"briefTitle":635,"officialTitle":636,"acronym":4,"eligibilityCriteria":637,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":252,"enrollmentInfo":638,"targetDuration":4,"studyType":52,"phases":639,"briefSummary":640,"conditions":641,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":642,"lastUpdatePostDateStruct":643,"startDateStruct":644,"completionDateStruct":645,"leadSponsor":647,"locationsCount":40},"100637568","phase-2-efficacy-and-safety-of-lp-005-injection-in-patients-with-moderate-to-severe-periodontitis-100637568","NCT07603713","Efficacy and Safety of LP-005 Injection in Patients With Moderate-to-Severe Periodontitis","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅱ Study to Evaluate the Efficacy and Safety of LP-005 Injection in Patients With Moderate-to-Severe Periodontitis","Inclusion Criteria:\n\n1. Aged 18 to 70 years (inclusive), with no restriction on sex.\n2. Clinically diagnosed with moderate to severe (Stage II or III) periodontitis according to the 2018 International Classification of Periodontal and Peri-Implant Diseases. participants must have at least 2 non-adjacent natural teeth (excluding third molars) in the dentition with a Probing Depth (PD) of 5 to 8 mm (inclusive), and at least 1 site per tooth with a BI score \\> 2.\n3. Participants and their partners must agree to practice effective non-pharmacological contraception from the time of signing the Informed Consent Form (ICF) until 3 months after the study completion. For female participants of childbearing potential, a negative pregnancy test result is required within 7 days prior to the first dose.\n4. Voluntary participation in the trial and signed approval of the ICF.\n\nExclusion Criteria:\n\n1. At the time of screening, the target tooth and\u002For adjacent teeth (as determined by the investigator to affect the target tooth) exhibit periapical periodontitis, pericoronitis, or combined pulp-periodontal lesions; or the participant has orthodontic appliances (including fixed lingual retainers, etc.);\n2. At screening, the target tooth and\u002For adjacent teeth (as determined by the investigator to affect the target tooth) are found by the investigator to have severe caries or caries requiring immediate treatment;\n3. At screening, the participant has a periodontal or dental abscess, or a tumor of the oral soft or hard tissues;\n4. Participants who have previously undergone periodontal surgery on the target teeth and\u002For adjacent teeth (as determined by the investigator to affect the target teeth), or who have undergone subgingival scaling and root planning (SRP) within 6 months prior to screening;\n5. Participants with a history of Neisseria meningitidis infection;\n6. Participants with a history of splenectomy or congenital asplenia;\n7. Participants with impaired immune function (e.g., HIV infection, neutropenia, complement deficiency, etc.);\n8. Participants with autoimmune diseases that the investigator determines may interfere with the evaluation of the study disease, such as Sjögren's syndrome, systemic lupus erythematosus, psoriasis, rheumatoid arthritis, etc.;\n9. Participants with poorly controlled blood pressure at screening, such as systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg;\n10. Participants with glycated hemoglobin (HbA1c) \\>7.5% or severe diabetic complications at screening;\n11. Participants with severe or poorly controlled systemic diseases at screening, as determined by the investigator, such as respiratory, gastrointestinal, cardiovascular, hematological, urological, neurological, or psychiatric disorders;\n12. Participants who have continuously taken medications deemed by the investigator to interfere with the study within 1 month prior to screening, such as nifedipine, phenytoin, or anticoagulants (e.g., warfarin);\n13. Participants who have received systemic antibiotic therapy within 3 months prior to screening;\n14. Participants who have taken nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids on a long-term basis (≥3 times per week) prior to screening;\n15. Participants with any of the following laboratory test results at the time of screening:\n\n    * ALT or AST \\> 2.5 times the upper limit of normal (ULN) or serum total bilirubin \\> 1.5 times ULN;\n    * Serum creatinine \\> 1.5 times the upper ULN;\n    * International Normalized Ratio (INR) ≥ 1.5 times ULN, or activated partial thromboplastin time (APTT) ≥ 1.5 times ULN (excluding participants currently receiving anticoagulant therapy);\n    * Platelet count (PLT) \\\u003C 100 × 10⁹\u002FL;\n16. Participants who test positive for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab), or Treponema pallidum antibody (TP-Ab) at screening;\n17. Participants with a history of malignant tumors within 5 years prior to screening;\n18. Participants with a history of heavy smoking (≥10 cigarettes per day) within 12 months prior to screening;\n19. Participants with known allergies to any drugs or materials used during surgery;\n20. Pregnant or breastfeeding women;\n21. Participants who have participated in other clinical trials within 30 days prior to screening or who plan to participate in other clinical trials during the study period;\n22. Participants assessed by the investigator as having other conditions rendering them unsuitable for participation in the clinical study.",{"count":20,"type":21},[329],"This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study designed to evaluate the clinical efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of multiple local injections of different doses of LP-005 injection in patients with moderate-to-severe periodontitis, and to investigate changes in biomarker levels.",[26],"2026-05-16",{"date":539,"type":32},{"date":566,"type":21},{"date":646,"type":21},"2027-03-23",{"name":648,"class":649},"Longbio Pharma (Suzhou) Co., Ltd.","INDUSTRY"]